Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
4.67
Dollar change
+0.14
Percentage change
3.09
%
Index- P/E- EPS (ttm)-2.23 Insider Own32.42% Shs Outstand42.18M Perf Week-11.39%
Market Cap196.98M Forward P/E- EPS next Y-3.20 Insider Trans17.11% Shs Float28.50M Perf Month-29.88%
Income-93.80M PEG- EPS next Q0.02 Inst Own62.53% Short Float2.31% Perf Quarter-36.38%
Sales51.13M P/S3.85 EPS this Y-18.96% Inst Trans-4.82% Short Ratio4.24 Perf Half Y-62.49%
Book/sh5.03 P/B0.93 EPS next Y-20.69% ROA-30.36% Short Interest0.66M Perf Year-51.35%
Cash/sh5.30 P/C0.88 EPS next 5Y- ROE-38.16% 52W Range3.08 - 13.85 Perf YTD-36.03%
Dividend Est.- P/FCF- EPS past 5Y-41.74% ROI-44.02% 52W High-66.28% Beta0.56
Dividend TTM- Quick Ratio6.24 Sales past 5Y1420.60% Gross Margin92.98% 52W Low51.62% ATR (14)0.44
Dividend Ex-Date- Current Ratio6.24 EPS Y/Y TTM-221.34% Oper. Margin-224.43% RSI (14)30.91 Volatility7.93% 7.89%
Employees179 Debt/Eq0.02 Sales Y/Y TTM-61.21% Profit Margin-183.44% Recom1.57 Target Price15.33
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q11.67% Payout- Rel Volume0.74 Prev Close4.53
Sales Surprise-31.33% EPS Surprise-86.84% Sales Q/Q-28.31% EarningsFeb 28 BMO Avg Volume155.49K Price4.67
SMA20-17.67% SMA50-26.51% SMA200-40.11% Trades Volume116,847 Change3.09%
Date Action Analyst Rating Change Price Target Change
Jun-09-23Upgrade Stifel Hold → Buy $11 → $16
Feb-03-23Downgrade Morgan Stanley Overweight → Equal-Weight $28 → $15
Jan-06-23Initiated CapitalOne Overweight $28
Apr-12-22Downgrade Stifel Buy → Hold $11
Mar-17-22Resumed Goldman Buy $43
Sep-23-21Initiated Stifel Buy $48
Sep-13-21Initiated H.C. Wainwright Buy $54
Jun-28-21Initiated Guggenheim Buy $46
Mar-01-21Initiated Berenberg Buy $51
Oct-28-20Initiated Northland Capital Outperform $38
Feb-29-24 07:05AM
Feb-28-24 07:36AM
07:05AM
Feb-20-24 10:00AM
Feb-15-24 07:05AM
04:45AM Loading…
Feb-13-24 04:45AM
Feb-12-24 04:05PM
Jan-25-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-29-23 04:05PM
Nov-20-23 08:19AM
Nov-15-23 07:00AM
Nov-09-23 11:38AM
08:16AM
07:00AM Loading…
07:00AM
Nov-07-23 07:00AM
Nov-06-23 11:35AM
07:00AM
Oct-13-23 09:40AM
Oct-11-23 09:35AM
Oct-09-23 09:35AM
Oct-03-23 07:00AM
Sep-20-23 04:26AM
Sep-19-23 07:00AM
Sep-06-23 07:00AM
Aug-31-23 10:12PM
Aug-16-23 02:54PM
Aug-09-23 05:40PM
04:05PM
03:30PM Loading…
Aug-05-23 03:30PM
Jul-16-23 10:36AM
Jun-08-23 09:49AM
07:00AM
Jun-07-23 04:05PM
Jun-06-23 07:00AM
Jun-05-23 06:36AM
Jun-02-23 07:00AM
May-22-23 07:00AM
May-14-23 08:04AM
May-12-23 06:19AM
May-11-23 06:13AM
May-09-23 06:55PM
04:05PM
May-03-23 09:55AM
Apr-28-23 04:05PM
Apr-18-23 02:32PM
10:15AM
Mar-29-23 07:25AM
Mar-14-23 04:58PM
Mar-02-23 05:39AM
Feb-28-23 08:15PM
04:05PM
Feb-06-23 05:18AM
Feb-02-23 07:00AM
Jan-24-23 04:33AM
Jan-20-23 09:55AM
Jan-19-23 07:00AM
Dec-27-22 05:34AM
Dec-19-22 07:00AM
Dec-02-22 10:54AM
09:35AM
Dec-01-22 09:55AM
Nov-16-22 05:35AM
Nov-14-22 09:55AM
Nov-09-22 05:35PM
04:05PM
Nov-07-22 07:00AM
Oct-13-22 11:08AM
Oct-12-22 09:10AM
Sep-07-22 07:17AM
07:00AM
Aug-11-22 06:55AM
Aug-04-22 06:35PM
04:05PM
Jun-30-22 01:08PM
Jun-07-22 07:00AM
Jun-02-22 03:26PM
12:30PM
11:01AM
08:00AM
Jun-01-22 06:03PM
04:05PM
May-09-22 07:00AM
May-05-22 08:35PM
04:05PM
09:04AM
May-04-22 05:25PM
Apr-20-22 11:00AM
Apr-13-22 08:24AM
Apr-12-22 09:32AM
Apr-11-22 04:05PM
Apr-08-22 01:00PM
Mar-30-22 10:17AM
Mar-08-22 04:30PM
Mar-07-22 12:07PM
07:00AM
Mar-04-22 05:14AM
Mar-01-22 05:35PM
04:15PM
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Segal Lloyd MitchellPRESIDENT AND CEOMar 27 '24Sale4.632,65012,27083,866Mar 27 06:54 PM
Forte SteveEVP, CHIEF FINANCIAL OFFICERMar 27 '24Sale4.628253,81242,212Mar 27 06:59 PM
Koehler MariaEVP, CHIEF MEDICAL OFFICERMar 27 '24Sale4.625002,310232,209Mar 27 06:56 PM
Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERMar 27 '24Sale4.624502,07972,768Mar 27 06:57 PM
Segal Lloyd MitchellPRESIDENT AND CEOMar 26 '24Sale4.642,65012,29686,516Mar 27 06:54 PM
Forte SteveEVP, CHIEF FINANCIAL OFFICERMar 26 '24Sale4.608253,79543,037Mar 27 06:59 PM
Koehler MariaEVP, CHIEF MEDICAL OFFICERMar 26 '24Sale4.605002,300232,709Mar 27 06:56 PM
Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERMar 26 '24Sale4.614502,07473,218Mar 27 06:57 PM
Segal Lloyd MitchellPRESIDENT AND CEOMar 25 '24Sale4.792,65012,69489,166Mar 27 06:54 PM
Forte SteveEVP, CHIEF FINANCIAL OFFICERMar 25 '24Sale4.798253,95243,862Mar 27 06:59 PM
Koehler MariaEVP, CHIEF MEDICAL OFFICERMar 25 '24Sale4.785002,390233,209Mar 27 06:56 PM
Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERMar 25 '24Sale4.784502,15173,668Mar 27 06:57 PM
Koehler MariaEVP, Chief Medical OfficerDec 11 '23Option Exercise2.2643,74698,755219,709Dec 12 04:19 PM
BVF PARTNERS L P/IL10% OwnerNov 16 '23Buy5.38295,7451,592,2025,309,432Nov 17 04:54 PM
BVF PARTNERS L P/IL10% OwnerNov 15 '23Buy5.00931,5564,657,6875,155,739Nov 17 04:54 PM
BVF PARTNERS L P/IL10% OwnerNov 02 '23Buy3.60783,7092,821,3524,662,402Nov 03 05:37 PM
Zinda MichaelEVP, Chief Scientific OfficerJun 07 '23Sale12.036,40477,04062,987Jun 09 04:25 PM
Zinda MichaelEVP, Chief Scientific OfficerJun 06 '23Sale12.041,20014,44869,391Jun 07 04:55 PM